Richard K. Cheng

University of Washington — United States

Medicine · Health Sciences

36h-index5.0kcitations348works5.92yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Chemotherapy-induced cardiotoxicity and mitigation(73), Cardiac Structural Anomalies and Repair(49), Mechanical Circulatory Support Devices(48), Heart Failure Treatment and Management(45), Transplantation: Methods and Outcomes(44)

Publications345 total

Association of sleep disturbance during breast cancer treatment and left ventricular ejection fraction decline: a prospective cohort study
Cardio-Oncology·2026Open Access
Racial differences in breast cancer-specific mortality and CVD-specific mortality after breast cancer in post-menopausal women
Cardio-Oncology·2025Open Access
Disparities in cardiometabolic and cardiovascular risk after breast cancer: the Pathways Heart Study
JNCI Cancer Spectrum·2025Open Access
Percutaneous management and outcomes of outflow graft obstruction in patients with left ventricular assist device: A single-center experience
JHLT Open·2025Open Access
Characteristics and Survival Among Patients With Cardiogenic Shock Undergoing Mitral Transcatheter Edge-to-Edge Repair
JACC Advances·2025Open Access
Donation after circulatory determination of death heart transplantation using simplified direct procurement: Expanding access
The Journal of Heart and Lung Transplantation·2025· 2 cited
Immune Checkpoint Inhibitor–Associated Cardiovascular Toxic Effects
JAMA Oncology·2025· 1 cited
Abstract 4368185: Serum Transthyretin Levels at Day 28 are Associated with Cardiovascular Outcomes: Insights From the ATTRibute-CM Study
Circulation·2025
Transthyretin Cardiac Amyloidosis Evaluation and Management: 2025 ACC Concise Clinical Guidance
Journal of the American College of Cardiology·2025· 2 cited
Donor-Derived Cell-Free DNA in Antibody-Mediated Rejection
JACC Heart Failure·2025· 2 citedOpen Access
From Mutation to Metabolism: Toxins, Mitochondria, and Integrative Orthomolecular Cancer Therapy (IOCT) — Implications for ASCVD and T2DM
Preprints.org·2025Open Access
Cardiovascular Outcomes in Patients With Cancer Undergoing Cardiac Implantable Electronic Device Implantation
Pacing and Clinical Electrophysiology·2025Open Access
Association of Life’s Essential 8 Cardiovascular Health Metrics With Heart Failure Subtypes in Older Women
JACC Heart Failure·2025
Effect of Acoramidis on Recurrent and Cumulative Cardiovascular Outcomes in ATTR-CM
Journal of the American College of Cardiology·2025· 3 citedOpen Access
HF STATS 2025: Heart Failure Epidemiology and Outcomes Statistics An Updated 2025 Report from the Heart Failure Society of America
Journal of Cardiac Failure·2025· 14 citedOpen Access
Evolving Cardioprotective Strategies in Cardio-Oncology: A Narrative Review
Current Cardiology Reports·2025· 1 cited
Prognostic significance of abdominal aortic calcification scores on dual-energy X-ray absorptiometry scans for mortality in cancer survivors: NHANES-based cohort study (2013–2019)
European Heart Journal Open·2025Open Access
Improvement in global longitudinal strain following plasma cell-directed therapy is associated with long-term survival among patients with AL amyloidosis
European Heart Journal Open·2025· 1 citedOpen Access
Cardiac Biomarkers as an Early Warning System in Transthyretin Cardiac Amyloidosis
Journal of the American College of Cardiology·2025
Antibody Mediated Rejection in the Contemporary Donor-Derived Cell-Free DNA Era: An Analysis of the Surveillance HeartCare Outcomes Registry
American Journal of Transplantation·2025
page 1 of 18Next →

Frequent Co-authors

Wayne C. Levy(8), Douglas Leedy(6), Claudius Mahr(6), Mathew S. Maurer(5), Kristen K. Patton(5), Todd Dardas(5), Sofia Carolina Masri(5), Ana Barac(5), Ray E. Hershberger(4), Hina W. Chaudhry(4), Alexi Vasbinder(4), April Stempien‐Otero(4), Daniel J. Lenihan(4), Anita Deswal(4), M. Kittleson(3), Gregg C. Fonarow(3), Paco E. Bravo(3), Susan Dent(3), Ana Morales(3), Daniel D. Kinnamon(3)